effects of valsartan combined with atorvastatin on cardiac function, myocardial enzymes and thyroxine levels in patients with chronic heart failure
Clicks: 352
ID: 163580
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
69.4
/100
352 views
282 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #15 of 96 articles by views in journal of communications
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objective: To observe the effects of valsartan combined with atorvastatin on cardiac function,
myocardial enzymes and thyroxine levels in patients with chronic heart failure (CHF).
Methods: 90 cases of CHF cases were divided into observation group and control group
according to the order of single and double number, 45 cases each. In the control group,
atorvastatin was given on the basis of conventional therapy, and the observation group was
given valsartan on the basis of the control group. After 6 months, the differences of cardiac
function indexes (LVEF, LVEDD, LVESD, E/A), myocardial enzymes (LDH, AST, CK, CKMB)
and thyroxine (TT3, TT4, FT3, FT4, TSH) in the two groups were observed. Results:
After treatment, LVEF and E/A in both groups increased significantly (P<0.05), while LVEDD
and LVESD decreased significantly (P<0.05), and LVEF (49.05±5.37)% and E/A (1.13±0.19)
are higher than the control group ,while LVEDD (51.55±5.26) mm and LVESD (38.87±3.61)
mm are lower than the control group, the difference was statistically significant (P<0.05); After
treatment, two groups of LDH, AST, CK, CK-MB were significantly decreased (P<0.05),
LDH, AST, CK and CK-MB in the observation group were (165.06±29.45) IU/L, (31.51±13.33)
IU/L, (96.45±29.58) mmol/L and (19.53±8.75) mmol/L respectively, lower than the control
group, the differences were statistically significant (P<0.05); After treatment, two groups
of TT3 and FT3 increased significantly (P<0.05) while TT4, FT4 and TSH levels had no
significant changes (P>0.05), the observation group TT3 and FT3 were respectively (1.37±0.33)
mol/L and (2.61±0.69) pmol/L , higher than the control group, the difference was statistically
significant (P<0.05). Conclusion: valsartan combined with atorvastatin in the treatment of
CHF, can improve cardiac function and myocardial protection effect, and can effectively
promote the recovery of thyroid hormone levels, better than the single use of atorvastatin.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (121 words).
Try re-searching for a better abstract.
| Reference Key |
wang12017journaleffects
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Xiao-Gang Wang1;De-Xuan Chen2;Kai Li1 |
| Journal | journal of communications |
| Year | 2017 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.